Tempest Therapeutics Inc
NASDAQ:TPST
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
S
|
Shinko Shoji Co Ltd
TSE:8141
|
JP |
|
TrueBlue Inc
NYSE:TBI
|
US |
|
T
|
Theme International Holdings Ltd
HKEX:990
|
HK |
|
F
|
Freshlocal Solutions Inc
TSX:LOCL
|
CA |
|
Tantech Holdings Ltd
NASDAQ:TANH
|
CN |
|
X
|
Xiamen Amoytop Biotech Co Ltd
SSE:688278
|
CN |
|
Xior Student Housing NV
XBRU:XIOR
|
BE |
|
C&D Property Management Group Co Ltd
HKEX:2156
|
CN |
Tempest Therapeutics Inc
EPS (Diluted)
Tempest Therapeutics Inc
EPS (Diluted) Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | EPS (Diluted) | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Tempest Therapeutics Inc
NASDAQ:TPST
|
EPS (Diluted)
-$8
|
CAGR 3-Years
37%
|
CAGR 5-Years
55%
|
CAGR 10-Years
50%
|
|
|
Abbvie Inc
NYSE:ABBV
|
EPS (Diluted)
$2
|
CAGR 3-Years
-29%
|
CAGR 5-Years
-3%
|
CAGR 10-Years
-3%
|
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
EPS (Diluted)
$6
|
CAGR 3-Years
23%
|
CAGR 5-Years
132%
|
CAGR 10-Years
-5%
|
|
|
Amgen Inc
NASDAQ:AMGN
|
EPS (Diluted)
$14
|
CAGR 3-Years
6%
|
CAGR 5-Years
3%
|
CAGR 10-Years
5%
|
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
EPS (Diluted)
$15
|
CAGR 3-Years
6%
|
CAGR 5-Years
8%
|
CAGR 10-Years
N/A
|
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
EPS (Diluted)
$41
|
CAGR 3-Years
3%
|
CAGR 5-Years
6%
|
CAGR 10-Years
22%
|
|
Tempest Therapeutics Inc
Glance View
Tempest Therapeutics, Inc.is a clinical-stage biotechnology company. The company is headquartered in South San Francisco, California and currently employs 17 full-time employees. The company went IPO on 2012-10-04. The firm is focused on developing therapeutics that combine both targeted and immune-mediated mechanisms to treat a wide range of tumors. The Company’s two clinical programs include TPST-1495 and TPST-1120. TPST-1120 is a selective antagonist of peroxisome proliferator-activated receptor. TPST-1120 is in Phase I and II trials in solid tumors, including a global randomized Phase Ib/II trial in combination with the standard-of-care first-line regimen of atezolizumab and bevacizumab in patients with advanced or metastatic hepatocellular carcinoma (HCC). TPST-1495, is a dual antagonist of EP2 and EP4, receptors of prostaglandin E2, and is in a Phase I monotherapy and combination trial in solid tumors.
See Also
What is Tempest Therapeutics Inc's EPS (Diluted)?
EPS (Diluted)
-8.1
USD
Based on the financial report for Sep 30, 2025, Tempest Therapeutics Inc's EPS (Diluted) amounts to -8.1 USD.
What is Tempest Therapeutics Inc's EPS (Diluted) growth rate?
EPS (Diluted) CAGR 10Y
50%
Over the last year, the EPS (Diluted) growth was 55%. The average annual EPS (Diluted) growth rates for Tempest Therapeutics Inc have been 37% over the past three years , 55% over the past five years , and 50% over the past ten years .
